Compare RACE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RACE | REGN |
|---|---|---|
| Founded | 1947 | 1988 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 73.2B |
| IPO Year | 2015 | 1995 |
| Metric | RACE | REGN |
|---|---|---|
| Price | $346.56 | $601.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 25 |
| Target Price | $477.86 | ★ $830.16 |
| AVG Volume (30 Days) | 675.6K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.26% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 6.75 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $7.91 | $12.45 |
| Revenue Next Year | $7.51 | $10.13 |
| P/E Ratio | ★ $34.59 | $91.29 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $312.51 | $503.25 |
| 52 Week High | $519.10 | $821.11 |
| Indicator | RACE | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 33.50 |
| Support Level | $322.01 | $591.52 |
| Resistance Level | $357.77 | $618.01 |
| Average True Range (ATR) | 8.09 | 15.52 |
| MACD | 1.56 | 1.36 |
| Stochastic Oscillator | 59.06 | 19.12 |
Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2025, the company sold 13,640 vehicles at an average price over EUR 520,000 with more than 80% of its vehicles being sold to existing Ferrari clients. Eighty-four percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2025, the Europe, Middle East, and Africa region accounted for 49% of revenue, the Americas was 32%, mainland China, Hong Kong, and Taiwan was 7%, and the rest of Asia was 12%.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.